Published on Wed Aug 11 2021

Binding of SEP-363856 within TAAR1 and the 5HT

Pramod C Nair, John O Miners, Ross A McKinnon, Christopher J Langmead, Karen J Gregory, David Copolov, Sherry Kit Wa Chan, Tarun Bastiampillai

Current medications for schizophrenia typically modulate dopaminergic neurotransmission. While affecting positive symptoms, antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairment. The recent positive clinical trial of the novel drug candidate SEP-363856, which targets non-dopamine receptors.

1
4
8
Abstract

Current medications for schizophrenia typically modulate dopaminergic neurotransmission. While affecting positive symptoms, antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairment. Moreover, newer 'atypical' antipsychotic drugs also have significant metabolic adverse-effects. The recent positive clinical trial of the novel drug candidate SEP-363856, which targets non-dopamine receptors (trace amine-associated receptor and the 5HT